Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.
Sundar Jagannath, MBBS
Advertisement
Articles by Sundar Jagannath, MBBS
Experts discuss the rapid advancements in BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma, highlighting improved response rates and treatment integration.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
SABCS 2025: The Top 5 Takeaways for Breast Cancer Research
2
FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC
3
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
4
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
5